12:00 AM
Aug 17, 2015
 |  BioCentury  |  Finance

Cross court

How Ra courted crossover investors for its series B

For private companies looking to court crossover investors, the lesson from Ra Pharmaceuticals Inc.'s $58.5 million series B round is that having a well-connected board is paramount.

"We had a board meeting last September when the discussion was about socializing the message," said President and CEO Doug Treco. "I wouldn't call it testing the waters; we were just out there getting more people aware of the story for the future."

Ed Mathers, a partner at NEA who sits on Ra's board, introduced the macrocycle company...

Read the full 428 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >